All In Biotech

Drug Trial Radar · NCT02579096

CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat

Last checked: Nov 20, 2026Latest source record: Mar 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 950 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

950

Actual

Start

Mar 6, 2017

Primary completion

Feb 1, 2021

Study completion Apr 15, 2021

Sponsor

Lead sponsor
VA Office of Research and DevelopmentFederal agency
Sponsor type
Federal agency
First posted
Oct 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum uric acid and therefore prevent further gout attacks. These therapies have never been compared at appropriate doses. Further, they will be studied in patients with kidney disease for the first time.

Conditions

  • Gout
  • Chronic Kidney Diseases

Interventions

  • allopurinol capsule, 100-800 mg by mouth once dailyDrug

    Patients will be up-titrated up to the dose required to reach target uric acid levels.

  • febuxostat tablet 40-120 mg by mouth once dailyDrug

    Patients will be up-titrated to the dose required to reach target uric acid levels.

  • Placebo, vehicle control (febuxostat-shaped)Drug

    Placebo tablets resembling febuxostat will be given with allopurinol.

  • Placebo, vehicle control (allopurinol-shaped)Drug

    Placebo capsules resembling allopurinol will be given with febuxostat.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3Time frame: Phase III of the study (weeks 49-72 of study duration)

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • VA Loma Linda Healthcare System, Loma Linda, CA

    Loma Linda, California

  • VA San Diego Healthcare System, San Diego, CA

    San Diego, California

  • San Francisco VA Medical Center, San Francisco, CA

    San Francisco, California

  • Miami VA Healthcare System, Miami, FL

    Miami, Florida

  • Edward Hines Jr. VA Hospital, Hines, IL

    Hines, Illinois

  • VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

    Boston, Massachusetts

  • Minneapolis VA Health Care System, Minneapolis, MN

    Minneapolis, Minnesota

  • Mayo Clinic Rochester MN ? RAIN 1

    Rochester, Minnesota

  • Kansas City VA Medical Center, Kansas City, MO

    Kansas City, Missouri

  • Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE

    Omaha, Nebraska

  • University of Nebraska Medical Center ? RAIN 5

    Omaha, Nebraska

  • Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY

    New York, New York

  • Asheville VA Medical Center, Asheville, NC

    Asheville, North Carolina

  • Sanford Bismarck Medical Center ? RAIN 2

    Bismarck, North Dakota

  • Cincinnati VA Medical Center, Cincinnati, OH

    Cincinnati, Ohio

  • VA Portland Health Care System, Portland, OR

    Portland, Oregon

  • Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA

    Philadelphia, Pennsylvania

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

    Pittsburgh, Pennsylvania

  • Yankton Medical Clinic ? RAIN 3

    Yankton, South Dakota

  • VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX

    Dallas, Texas

  • VA Salt Lake City Health Care System, Salt Lake City, UT

    Salt Lake City, Utah

  • White River Junction VA Medical Center, White River Junction, VT

    White River Junction, Vermont

  • Salem VA Medical Center, Salem, VA

    Salem, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.